Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma.

Barailler H, Salomon G, Dutriaux C, Prey S, Gérard E, Dousset L, Mertens C, Beylot-Barry M, Meyer N, Pham-Ledard A.

J Geriatr Oncol. 2020 Mar 18. pii: S1879-4068(19)30392-3. doi: 10.1016/j.jgo.2020.03.003. [Epub ahead of print] No abstract available.

PMID:
32199777
2.

Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study.

Montaudié H, Viotti J, Combemale P, Dutriaux C, Dupin N, Robert C, Mortier L, Kaphan R, Duval-Modeste AB, Dalle S, De Quatrebarbes J, Stefan A, Brunet-Possenti F, Kogay M, Picard-Gauci A, Poissonnet G, Peyrade F.

Oncotarget. 2020 Jan 28;11(4):378-385. doi: 10.18632/oncotarget.27434. eCollection 2020 Jan 28.

3.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A Jr, Gasal E, Mookerjee B, Chapman PB.

Eur J Cancer. 2020 Jan;125:114-120. doi: 10.1016/j.ejca.2019.10.033.

PMID:
31864178
4.

Quality-of-life assessment in French patients with metastatic melanoma in real life.

Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I.

Cancer. 2020 Feb 1;126(3):611-618. doi: 10.1002/cncr.32554. Epub 2019 Oct 22.

PMID:
31639198
5.

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.

Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, Dutriaux C, Guillot B, Jeudy G, Mateus C, Monestier S, Mortier L, Poulalhon N, Prey S, Robert C, Vabres P, Lebbe C, Meyer N, Basset-Seguin N.

J Clin Oncol. 2019 Dec 1;37(34):3275-3282. doi: 10.1200/JCO.18.00794. Epub 2019 Oct 14.

PMID:
31609670
6.

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.

Eur J Cancer. 2019 Sep;119:97-106. doi: 10.1016/j.ejca.2019.07.016. Epub 2019 Aug 19.

7.

Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature.

de Vries-Brilland M, Sionneau B, Dutriaux C, Blay JY, Ravaud A, Gross-Goupil M.

Clin Genitourin Cancer. 2019 Aug;17(4):e721-e723. doi: 10.1016/j.clgc.2019.02.012. Epub 2019 Mar 15. No abstract available.

PMID:
31109800
8.

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!

Luherne C, Darrigade AS, Dutriaux C, Prey S, Milpied B.

JAAD Case Rep. 2019 Apr 28;5(5):422-423. doi: 10.1016/j.jdcr.2019.02.033. eCollection 2019 May. No abstract available.

9.

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.

Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C; for MelBase.

JAMA Dermatol. 2019 Jun 1;155(6):673-678. doi: 10.1001/jamadermatol.2019.0425.

PMID:
31042256
10.

Reply to E. Hindié and K.R. Hess.

Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A.

J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. No abstract available.

PMID:
30939092
11.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.

Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.

PMID:
30928620
12.

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.

Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, Lebbe C.

Eur J Cancer. 2019 May;112:38-46. doi: 10.1016/j.ejca.2019.02.009. Epub 2019 Mar 22.

PMID:
30909072
13.

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.

Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A.

Eur J Dermatol. 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448.

PMID:
30698147
14.

Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma.

Leroy V, Gerard E, Dutriaux C, Prey S, Gey A, Mertens C, Beylot-Barry M, Pham-Ledard A.

Cancer Immunol Immunother. 2019 Apr;68(4):545-551. doi: 10.1007/s00262-019-02298-9. Epub 2019 Jan 19.

PMID:
30661086
15.

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma.

Mignard C, Deschamps Huvier A, Gillibert A, Duval Modeste AB, Dutriaux C, Khammari A, Avril MF, Kramkimel N, Mortier L, Marcant P, Lesimple T, Gaudy-Marqueste C, Lesage C, Machet L, Aubin F, Meyer N, Beneton N, Jeudy G, Montaudié H, Arnault JP, Visseaux L, Trabelsi S, Amini-Adle M, Maubec E, Le Corre Y, Lipsker D, Wierzbicka-Hainaut E, Litrowski N, Stefan A, Brunet-Possenti F, Leccia MT, Joly P.

J Oncol. 2018 Dec 2;2018:1908065. doi: 10.1155/2018/1908065. eCollection 2018.

16.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.

JAMA Oncol. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271.

17.

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.

Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I.

Eur J Cancer. 2018 Dec;105:33-40. doi: 10.1016/j.ejca.2018.09.026. Epub 2018 Oct 29.

PMID:
30384014
18.

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV.

J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219. [Epub ahead of print]

19.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628
20.

[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie].

Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G.

Bull Cancer. 2018 Sep;105(9):780-789. doi: 10.1016/j.bulcan.2018.06.002. Epub 2018 Aug 14. French. No abstract available.

PMID:
30115366
21.

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.

Dupuis F, Lamant L, Gerard E, Torossian N, Chaltiel L, Filleron T, Beylot-Barry M, Dutriaux C, Prey S, Gros A, Jullie ML, Meyer N, Vergier B.

Br J Cancer. 2018 Jul;119(2):193-199. doi: 10.1038/s41416-018-0168-9. Epub 2018 Jul 5.

22.

[Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie].

Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G.

Ann Dermatol Venereol. 2018 Jun - Jul;145(6-7):413-422. doi: 10.1016/j.annder.2018.03.165. Epub 2018 Apr 25. French. No abstract available.

PMID:
29703640
23.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
24.

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Tétu P, Mangana J, Dummer R, Dutriaux C, Beneton N, Dalle S, Meyer N, Oriano B, Michielin O, Lebbe C.

Eur J Cancer. 2018 Apr;93:147-149. doi: 10.1016/j.ejca.2018.01.062. Epub 2018 Feb 12. No abstract available.

PMID:
29449059
25.

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A.

Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13.

26.

Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo.

Boniface K, Dutriaux C, Prey S, Taieb A, Seneschal J.

J Am Acad Dermatol. 2018 Jan;78(1):e17-e18. doi: 10.1016/j.jaad.2017.08.028. No abstract available.

PMID:
29241800
27.

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM.

Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16.

PMID:
29146737
28.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J.

Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.

29.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM.

N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.

30.

Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma.

Rousset M, Dutriaux C, Bosco-Lévy P, Prey S, Pham-Ledard A, Dousset L, Gérard E, Bouchet S, Canal-Raffin M, Titier K, Molimard M.

Clin Chim Acta. 2017 Sep;472:26-29. doi: 10.1016/j.cca.2017.07.012. Epub 2017 Jul 12.

PMID:
28709799
31.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.

Eur J Cancer. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033. Epub 2017 Jun 22.

PMID:
28648698
32.

An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.

Rousset M, Titier K, Bouchet S, Dutriaux C, Pham-Ledard A, Prey S, Canal-Raffin M, Molimard M.

Clin Chim Acta. 2017 Jul;470:8-13. doi: 10.1016/j.cca.2017.04.009. Epub 2017 Apr 12.

PMID:
28412197
33.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K.

Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9.

PMID:
28284557
34.

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.

Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, Taieb A, Dutriaux C, Prey S, Boniface K, Seneschal J.

J Am Acad Dermatol. 2017 May;76(5):863-870. doi: 10.1016/j.jaad.2016.10.044. Epub 2017 Jan 13.

PMID:
28094061
35.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J.

Lancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30.

PMID:
27480103
36.

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.

Mouriaux F, Servois V, Parienti JJ, Lesimple T, Thyss A, Dutriaux C, Neidhart-Berard EM, Penel N, Delcambre C, Peyro Saint Paul L, Pham AD, Heutte N, Piperno-Neumann S, Joly F.

Br J Cancer. 2016 Jun 28;115(1):20-4. doi: 10.1038/bjc.2016.119. Epub 2016 Jun 2.

37.

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.

Le Tourneau C, Dreno B, Kirova Y, Grob JJ, Jouary T, Dutriaux C, Thomas L, Lebbé C, Mortier L, Saiag P, Avril MF, Maubec E, Joly P, Bey P, Cosset JM, Sun JS, Asselain B, Devun F, Marty ME, Dutreix M.

Br J Cancer. 2016 May 24;114(11):1199-205. doi: 10.1038/bjc.2016.120. Epub 2016 May 3.

38.

Genomic and viral findings in two different primary Merkel cell carcinomas in a 76-year-old woman.

Dousset L, Dutriaux C, Taïeb A, Chibon F, Foulongne V, Frouin E, Jullié ML, Jouary T.

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):e42-e43. doi: 10.1111/jdv.13669. Epub 2016 Mar 30. No abstract available.

PMID:
27027702
39.

Primary digestive melanoma in association with tubular adenoma: a case report illustrating the distinction from metastatic colonic melanoma.

Furudoï A, Caumont C, Dutriaux C, Cappellen D, Goussot JF, Vergier B, Merlio C, Barberis C, Merlio JP, Gros A.

Hum Pathol. 2016 Feb;48:167-71. doi: 10.1016/j.humpath.2015.09.025. Epub 2015 Oct 9.

PMID:
26616020
40.

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J.

Lancet Oncol. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. Epub 2015 May 13.

PMID:
25981813
41.

Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.

Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, Bordone O, Gay A, Zahaf K, Poissonnet G, Lacour JP, Bahadoran P, Ballotti R, Gros A, Dutriaux C, Saiag P, Merlio JP, Vergier B, Emile JF, Hofman V, Hofman P.

J Am Acad Dermatol. 2015 May;72(5):786-93. doi: 10.1016/j.jaad.2015.01.012. Epub 2015 Feb 7.

PMID:
25659223
42.

Nivolumab in previously untreated melanoma without BRAF mutation.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA.

N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.

43.

Lichen sclerosus mimicking halo-naevus comedonicus.

Jouary T, Guillet S, Droitcourt C, Dutriaux C, Ezzedine K, Goussot JF, Taieb A.

J Eur Acad Dermatol Venereol. 2016 Feb;30(2):375-6. doi: 10.1111/jdv.12800. Epub 2014 Oct 29. No abstract available.

PMID:
25354312
44.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A.

N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.

45.

Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?

Gey A, Milpied B, Dutriaux C, Mateus C, Robert C, Perro G, Taieb A, Ezzedine K, Jouary T.

J Eur Acad Dermatol Venereol. 2016 Jan;30(1):178-9. doi: 10.1111/jdv.12685. Epub 2014 Aug 29. No abstract available.

PMID:
25175726
46.

Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.

Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, Thellier S, Jouary T, Grob JJ, Richard MA, Templier C, Sakji L, Guillot B, Paul C, Meyer N.

Acta Derm Venereol. 2014 Jan;94(1):45-9. doi: 10.2340/00015555-1654.

47.

Merkel cell carcinoma: complete clinical remission associated with disease progression.

Bertolotti A, Conte H, François L, Dutriaux C, Ezzedine K, Mélard P, Vergier B, Taieb A, Jouary T.

JAMA Dermatol. 2013 Apr;149(4):501-2. doi: 10.1001/jamadermatol.2013.2596. No abstract available.

PMID:
23715411
48.

Metastatic melanoma with leukaemia-like evolution.

Bertolotti A, Conte H, Amazan E, Dutriaux C, Ezzedine K, Parrens M, Vergier B, Taieb A, Jouary T.

Acta Derm Venereol. 2013 Nov;93(6):729-30. doi: 10.2340/00015555-1581. No abstract available.

49.

[Management of adverse effects of targeted therapy toxicities in oncology].

Coquan E, Henri P, de Raucourt S, Lireux B, Lamy E, Delcambre C, Sevin E, Dutriaux C, Bouhier-Leporrier K, Gervais R, Joly F.

Rev Prat. 2012 Jan;62(1):17-25. French.

PMID:
22335060
50.

Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma--a report of eight cases.

Giacchero D, Barrière J, Benezery K, Guillot B, Dutriaux C, Mortier L, Lacour JP, Thyss A, Peyrade F.

Clin Oncol (R Coll Radiol). 2011 Dec;23(10):716-8. doi: 10.1016/j.clon.2011.07.007. Epub 2011 Aug 9. No abstract available.

PMID:
21831617

Supplemental Content

Loading ...
Support Center